Industrial Policy & Trade Monitor· 2666 actions· ✨ 89 recent

BIS amended the Export Administration Regulations (EAR) to revise Country Group designations for Ukraine, Mexico, and Cyprus, effective immediately on publication (85 FR 83756, FR Doc 2020-26552). Ukraine was elevated from Country Group D to Country Group B, making it newly eligible for eight EAR license exceptions (LVS, TMP, RPL, GFT, BAG, AVS, APR, ENC) and shifting dual-use export licensing to a standard national-security basis. Mexico and Cyprus were simultaneously added to Country Group A:6, granting both countries access to Strategic Trade Authorization (STA) exceptions for less-sensitive CCL-controlled items. The changes reflect each country's multilateral export-control regime membership and policy alignment with U.S. national security interests.

Effective 17 August 2020 (published Federal Register 20 August 2020, Vol. 85 No. 162, FR Doc 2020-17908), BIS issued a final rule clarifying that Entity List license requirements under the Export Administration Regulations (EAR) apply to listed entities regardless of their role in a transaction — as purchaser, intermediate consignee, ultimate consignee, or end-user. Prior regulatory text had been read as applying license requirements only when a listed entity was the ultimate consignee or end-user; this rule amends 15 CFR §§ 744.11 and 744.16 and the introductory text of Supplement No. 4 to Part 744 to close that gap. The clarification is substantively a housekeeping rule (no new entities are listed or delisted), but it removes an exploitable interpretive loophole in Entity List enforcement and was published the same day as the major Huawei affiliate expansion (FR Doc 2020-18213).

The Investitionskontrollgesetz (InvKG, "Investment Control Act") is Austria's horizontal, statutory FDI screening regime. Published as Article 1 of the Federal Law BGBl. I Nr. 87/2020 on 24 July 2020 and entering into force on 25 July 2020, the Act replaced the previous narrow §§25a–25e Außenwirtschaftsgesetz 2011 (Foreign Trade Act) regime — under which fewer than 10 permits were issued from 2013 to mid-2020 — and transposes EU Regulation 2019/452 establishing a framework for the screening of foreign direct investments into the Union. The InvKG introduces mandatory ex-ante notification and approval of non-EU / non-EEA / non-Swiss acquisitions where the acquirer crosses any of the 10% / 25% / 50% voting-rights thresholds in an Austrian target operating in the critical sectors listed in Annex Part 1 (especially sensitive: defence, energy / water / telecoms critical infrastructure, dual-use technology, cybersecurity, AI, quantum technology, robotics, semiconductors, biotech, health, vaccines) and 25% / 50% in the sectors listed in Annex Part 2 (broader, including media, food-security, electronic communications infrastructure, financial infrastructure). Administered by the Bundesministerium für Arbeit und Wirtschaft (BMAW), with case decisions taken in coordination with the Komitee für Investitionskontrolle (inter-ministerial Investment Control Committee) and, where the case is escalated to the EU cooperation mechanism, the Commission and EU peer Member States. The InvKG is Austria's functional peer of US CFIUS / FIRRMA, UK NSI Act 2021, Germany AWG §§55–62, France Décret 2014-479 / R. 151-1 et seq., Italy Golden Power Decree, Netherlands Wet Vifo, Denmark investeringsscreeningsloven, and Belgium ISC. Sunset clause: originally limited to 30 June 2022 under §17(2) InvKG; permanently extended by BGBl. I Nr. 80/2022 of 14 July 2022.

The Department of Pharmaceuticals notified the Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) on 21 July 2020 via Gazette Notification, with an outlay of Rs 6,940 crore (~USD 920m) over FY 2020-21 to FY 2027-28. The scheme covers 41 identified critical bulk-drug products across four target segments — fermentation-based (Key Fermentation; Niche Fermentation) and chemical synthesis-based (Key Chemical Synthesis; Niche Chemical Synthesis) — paying 20% incentive on incremental sales for fermentation-based products (years 1-4) tapering to 15% (year 5) and 5% (year 6), and a flat 20% over 5 years for chemically-synthesised products. The stated objective is to reduce India's ~70% bulk-drug import dependence on China by establishing greenfield domestic manufacturing capacity with at least 90% domestic value addition for fermentation products and 70% for chemical-synthesis products.